Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...

Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...

Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...

Teijin Automotive Technologies has announced its name: CSP. This rebranding, effective July 1, 2025, marks the company’s ...

Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 22.9% in the afternoon session after the ...

This week on "The Readout LOUD" podcast, a mother whose son has Duchenne muscular dystrophy shares her perspective on Sarepta ...

According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

The top financial leader at Thermo Fisher Scientific Inc. plans to retire from the company in 2026 after more than a decade ...

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc.